View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 12, 2019

FDA rejects Helius Medical Technologies’ PoNS device

The US Food and Drug Administration (FDA) has rejected Helius Medical Technologies’ premarket submission for the Portable Neuromodulation Stimulator (PoNS) device due to a lack of data. 

The US Food and Drug Administration (FDA) has rejected Helius Medical Technologies’ premarket submission for the Portable Neuromodulation Stimulator (PoNS) device due to a lack of data.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

Designed to be used in conjunction with physical therapy, PoNS is intended for the treatment of chronic balance deficit caused by mild-to-moderate traumatic brain injury.

Treatment involves the delivery of neuromodulation to stimulate cranial nerves, which is claimed to restore neurological function.

The company filed a submission to the FDA in September last year. Its application included findings from two double-blind, randomised, controlled clinical trials that evaluated the safety and efficacy of PoNS in a total of 163 participants.

"Helius remains committed to generating the data to pursue a de novo classification and 510(k) clearance of our PoNS device in the future."

The regulator has rejected the application stating that it does not have enough evidence that the effects observed in the clinical trials were due to the independent effects of the medical device.

The FDA noted that patients in both the treatment and control arms experienced improvements from baseline for all of the clinical endpoints.

The agency added that the neurotech company can resubmit its application in the future with additional data.

In a press release, Helius Medical said that the FDA’s review did not identify any device-related serious adverse events in the clinical trials.

Helius Medical Technologies CEO Philippe Deschamps said: “We are understandably disappointed by the agency’s decision to decline our request for de novo classification and 510(k) clearance, but Helius remains committed to generating the data to pursue a de novo classification and 510(k) clearance of our PoNS device in the future for the treatment of patients with chronic balance deficit due to mmTBI, in order to bring our innovative therapy to more than 1.5 million Americans suffering from this condition.”

PoNS currently holds regulatory approval in Canada and is being reviewed in the European Union (EU).

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network